Size | Price | |
---|---|---|
500mg | ||
1g | ||
Other Sizes |
Targets |
Metabotropic glutamate receptor (mGluRs)
|
---|---|
ln Vitro |
In hippocampal slices, MCPG (300 μM, 1, and 3 mM) suppresses the concentration-dependent increase in phosphoinositide (PPI) hydrolysis produced by 1S, 3R-ACPD [3]. MCPG (20 mM, 200 mM) suppresses tetanus-induced short-term potentiation (STP) (200 mM) and specifically blocks long-term potentiation (LTP) (20 mM) [3].
(S)-MCPG (100 μM) had no observable influence on spine production or removal mechanisms in WT slice cultures. (S)-MCPG inhibits TBS-induced increases in spine turnover and interferes with activity-dependent central stabilizing mechanisms in hippocampal slice cultures [1]. |
ln Vivo |
In male Vesta rats, tetanic stimulation-induced potentiation of the dentate gyrus field excitatory postsynaptic potential (fEPSP) can be eliminated by MCPG (intraventricular injection) [3].
Partial reversal of spine dynamics deficits in Fmr1-KO mice by a metabotropic glutamate receptor antagonist [1]
We then investigated whether these defects could be reversed, and tested the effects of the metabotropic glutamate receptor antagonist MCPG (100 μm) on spine dynamics. In WT slice cultures, MCPG had no detectable effects on basal spine formation or elimination mechanisms (Fig. 3A and B). However, it prevented the increase in spine turnover triggered by TBS (Fig. 3A and B; new spines: 23.8 ± 3.3%, n = 6, 233 spines vs. 42.4 ± 7.9%, n = 5, 240 spines, P < 0.05; lost spines: 20.8 ± 2.4% vs. 43.7 ± 8.8%, P < 0.05). It also interfered with the mechanisms of activity-dependent spine stabilization. In WT mice, MCPG significantly reduced the differential stability of enlarged vs. non-enlarged spines following TBS (Fig. 3C; circles: ns: non-significant difference, two-way anova), consistent with evidence suggesting an involvement of metabotropic receptors in LTP induction mechanisms (Anwyl, 2009). In Fmr1-KO mice, MCPG had three main effects. First, it restored the level of basal turnover by enhancing both newly formed and lost spines per 24 h (Fig. 3A and B: new spines: 17.0 ± 3.2% vs. 9.3 ± 1.3%, n = 6, 8, P < 0.05; lost spines: 15.2 ± 2.5% vs. 9.5 ± 1.5%, n = 6, 8, P < 0.05), consistent with the idea that the decreased turnover observed in Fmr1-KO mice could be due to an over-activation of metabotropic receptors (Pfeiffer & Huber, 2007). Second, it reduced the increased sensitivity of spine turnover to activity: new spine formation still increased following TBS, but to a lesser extent (Fig. 3A; 27.2 ± 3.6%, n = 5 cells, 237 spines vs. 15.6 ± 3.0%, n = 7, 274 spines, P < 0.05). However, the changes in spine loss following TBS stimulation did not reach statistical significance (Fig. 3B; P = 0.20). Thus, MCPG normalized basal spine dynamics and reduced the sensitivity of spine turnover to activity. Third, MCPG improved the general stability of spines [Fig. 3D; compare with (circles) and without MCPG (squares), P < 0.05, two-way anova]. However, MCPG failed to improve the defects in activity-dependent spine stabilization. Enlarged and non-enlarged spines showed the same stability following TBS, and there was no preferential stabilization of enlarged spines (Fig. 3D; circles, ns: non-significant, n = 5 cells, 237 spines analysed). Thus, MCPG improved the general stability of spines but did not restore mechanisms of activity-dependent spine stabilization.[1] The effects of the metabotropic glutamate receptor antagonist (+)-alpha-methyl-4-carboxyphenylglycine (MCPG) on performance in a water maze and in context-specific associative learning were examined in rats previously implanted with cannulae. MCPG (20.8 micrograms) injected intraventricularly (i.c.v.) before testing impaired the performance of rats in the spatial version of the Morris water maze, but 1/10 of this dose did not. Memory retention, evaluated 24 hr post-training, was also affected by the high dose of MCPG. However, performance in a cued version of the water maze was not impaired by the high dose, excluding effects of the drug on perceptual faculties. The effects of the MCPG were further characterized on performance in another hippocampus-dependent spatial learning task, the context-dependent fear conditioning task. MCPG (20.8 micrograms, i.c.v.) did not interfere with conditioned freezing to context in this task. For comparison, a group of rats was injected with the NMDA receptor blocker MK801. MK801 at a dose that disrupted the performance in the spatial version of the Morris water maze (0.08 mg/kg), significantly reduced freezing compared to controls. These experiments indicate that MCPG-sensitive metabotropic receptors may be required for only a restricted subset of spatial learning tasks, while NMDA receptors may play an integral role in all spatial learning.[2] Morris water maze [2] During the 4 days of training, both the MCPG-treated (at the high dose) and control animals showed significant improvement in performance, indicated by the decrease in both the time of reaching the platform [F(3,108)=107.5; p<0.01] and the distance of the animal from the platform [F(3,108)=77.4; p<0.01] (Fig. 1). Animals given MCPG, however, were significantly slower to learn the task. MCPG-treated rats took longer to reach the platform [F(1,35)=9.6; p<0.01] and their distance from the platform was longer over the training period [F(1,35)=9.9; p<0.01] than vehicle-injected animals. On days 2 and 3, MCPG rats had a significant longer escape latency (p<0.01, Fig. 1(A)) and their measure of search error was significantly longer on each of the first 3 days (p<0.01; Fig. 1(B), Newman–Keuls post-hoc test). On day 4, MCPG-treated animals reached the same level of performance as control animals. Contextual fear conditioning [2] As an alternative measure of learning, we tested the effects of MCPG on groups of rats in a context-specific associative learning. In the training phase of fear conditioning, rats were placed in a shocking chamber and given three footshocks during one 6-min session for 2 days. Rats were then returned to the shocking chamber 24 hr later and monitored for freezing behavior. Infrared photocells monitored the animal's activity and in the test phase a video camera recorded the session to be reviewed by an experimenter off-line. Fig. 5(A) shows the average activity of the animals in the first day of training. Both groups decreased their activity due to the occurrence of the shock [F(5,70)=5.6; p<0.01], but there was no statistical difference between the two groups. Neither motor activity nor freezing were influenced by MCPG during the test on day 3 compared to controls (Fig. 5(B)). Both groups froze more often after the first minute and less towards the end of the 6-min session [F(5,70)=7.6; p<0.01]. These results show that the impairment caused by MCPG 20.8 μg in the spatial learning water maze does not correlate with a similar effect on contextual learning. |
Cell Assay |
Confocal imaging and electrophysiology [1]
Four days after transfection, slice cultures were imaged repetitively using an Olympus Fluoview confocal microscope as described (Dubos et al., 2012). Secondary or tertiary dendritic segments (35–45 μm) on apical dendrites of CA1 pyramidal neurons in the stratum radiatum were visualized at 0, 5, 24, 48 and 72 h. Z-stack images were analysed using Osirix software and cross-checked with another experimenter. All protrusions were included in the analysis, and stability was assessed as the fraction of spines still present at later times. Spines were considered to enlarge if the spine head width increased by more than 0.1 μm between the 0 and 5 h time points. All data are given with n being the number of dendritic segments analysed considering one dendritic segment per neuron and one neuron per slice culture. When appropriate, we also give the total number of spines analysed in the pool of experiments. For electrophysiological recordings, hippocampal cultures or acute slices (4–6-week-old mice) were maintained in an interface chamber as described (De Roo et al., 2008b), perfused in a medium with the following composition (in mm): NaCl, 124; KCl, 1.6; MgCl, 1.5; CaCl2, 2.5; KH2PO4, 1.2; NaHCO3, 24; glucose, 10; ascorbic acid, 2; bubbled with 95% O2 and 5% CO2. Theta-burst stimulation (TBS) consisted of five trains at 5 Hz, each composed of four pulses at 100 Hz, repeated three times at 10-s intervals. Field excitatory postsynaptic potential slopes and amplitudes were measured using IGOR software. Western blot [1] The effect of BpV on AKT phosphorylation on the S473 site was tested in hippocampal slice cultures maintained 12–14 days in vitro and treated with 15 nm BpV, as well as on 4–6-week-old mice injected i.p. with BpV [30 μg/100 g in saline (200 μL)]. The tissue was lysed on ice 30 min or 1–4 h after treatments for slices and animals, respectively, using a solution containing (in mm): NaCl, 150; Tris-HCl, 50, pH 7.4; EDTA, 2; dithiothreitol, 1; 1% Triton X-100, 10% glycerol, complete protease inhibitor tablet, completed with phosphatase inhibitors (in mm): sodium orthovanadate, 1; para-nitrophenylphosphate, 20; β-glycerophosphate, 20; okadaic acid, 50 ng/mL. Lysates were sonicated, and 30 μg of total protein put on Nupage 4–12% Bis-Tris gel. Gels were run in 3-(N-morpholino)propanesulfonic acid sodium dodecyl sulfate buffer and transferred to nitrocellulose membranes. Phospho-AKT immunoblotting was performed using 1 : 3000 dilution of the primary rabbit monoclonal antibody against phosphoSer473. Densitometric analysis of the pAKT band of 60 kDa was normalized by β-actin immunoblot and expressed as a function of WT values (monoclonal, 1 : 20 000). |
Animal Protocol |
Animal/Disease Models: Morris water maze learning in male Lister-Hooded rats [2]
Doses: 20 μg Route of Administration: intracerebroventricular injection; 20 μg; 4 days Experimental Results: Impaired rat performance in the spatial version of the Morris water maze , but 1/10 of that dose did not. Animals and Morris water maze [1] Twenty male adult Fmr1-KO mice (FVB.129P2-Pde6b+ Tyrc-ch Fmr1tm1Cgr/J) and 20 male adult WT controls (FVB.129P2-Pde6b+ Tyrc-ch/AntJ) were used. Mice were individually identified and housed according to the Swiss legislation on animal protection. One Fmr1-KO and one WT mice were used for pilot tests; the final sample (19 Fmr1-KO and 19 WT) was divided into two groups: nine mice were treated with BpV and 10 received the vehicle. The mice were trained in a Morris water maze with four daily trials during four consecutive days. At day 5, a probe trial was run in the absence of the escape platform. Immediately after, mice received either an i.p. injection of BpV [30 μg/100 g in saline (200 μL)] or an i.p. injection of 200 μL saline. One hour later, all mice started a novel, four-trial training session with the platform in the opposite quadrant (reversal learning). Reversal training continued for two more days; treatment with BpV or saline was repeated accordingly. At day 8, a second probe test was run. Swim paths were videorecorded and analysed by a videotracking system. Variables assessed were escape latencies, times spent in target quadrants and platform place proximity indices (PIs), calculated by measuring the average distances to the platform [(PI probe1 − PI probe2)/(PI probe1 + PI probe2)×100]. Animals were allowed at least 7 days to recover from surgery and were handled daily during this period. They were housed individually for the remainder of the experiment. At the time of behavioral testing, the xstylets were replaced by 33-gauge injection needles connected to Hamilton microsyringes. MCPG or vehicle was administered intraventricularly (i.c.v.) in a volume of 5 μl delivered at a rate of approximately 1 μl/min. The needle was left in place for an additional 1–2 min after completion of the injection to allow diffusion of the drug. The high dose (20.8 μg) or the low dose (2.1 μg) of MCPG were prepared daily and stored at room temperature. At the end of each experiment cannula placements were examined by Nissl staining. [2] Behavioral methods [2] Morris water maze/spatial task [2] Two experiments using the metabotropic glutamate antagonist MCPG were conducted with this procedure. In the first experiment, the high dose of MCPG (20.8 μg) was used. Thirty-six rats were trained in the Morris water maze (Morris, 1984), consisting of a circular pool, 120 cm diameter, filled with water rendered opaque by milk and maintained at 26±1°C. The wall of the pool, 60 cm higher than the water level, was painted white. A platform, 10 cm in diameter and submerged by 2–3 cm, represented the escape from the water. The day before testing, animals were given 2 min each of free swimming in the pool to acclimatize them to the water. The rats were placed in a different starting position (among six possible) in each trial. The platform was always left in a fixed location throughout the 4-day training experiment. Animals were allowed 90 sec to locate the platform. Rats that had not found the platform after 90 sec were placed on it and allowed to remain there for the 60 sec intertrial time. Animals were given 4 trials a day for 4 consecutive days. MCPG (n=18) or vehicle (n=18) was injected i.c.v. 5 min before the start of the session every day. A computer-assisted program measured the path and time taken by each animal to reach the platform. While swimming, the proximity of the animal's position with respect to the target was also analyzed by the computer system. This measure, called the “search error”, represents the corrected cumulative distance from the escape platform (Gallagher et al., 1993). A proximity measure was calculated each second by averaging the distance between the rat and the target platform 10 times per second. A correction procedure was used to account for the six different starting points. Cumulative distance was employed on training trials and mean distance from the target was used on the fifth day during the probe trial (for more detail, see Gallagher et al., 1993). Twenty-four hours after the last training session, the animals were tested in a single probe trial for retention of spatial memory. Rats were divided into four groups before the probe trial: one group (MCPG/MCPG) was injected with a further dose of MCPG as on previous days (n=9); a second group (n=9) (MCPG/vehicle) had been injected with MCPG during the previous training sessions but received vehicle injection before the probe trial; a third group (vehicle/vehicle) received vehicle as it did in the past days (n=9); and the final group (vehicle/MCPG) was injected with MCPG after receiving only vehicle before (n=9), to test possible acute effects of MCPG on memory retention. The platform was removed from the pool in this trial, and the rats were allowed to swim for 20 sec. Time spent in each quadrant of the pool (Morris et al., 1986) and the averaged distance of the animal from where the target had been previously (Gallagher et al., 1993), were used to estimate memory retention. A second experiment was run with a new group of rats previously implanted with cannulae into the right lateral ventricle. A dose of MCPG (2.1 μg) 10 times lower than in the previous experiment was used, but all the procedures were identical. MCPG (n=8) or vehicle (n=10) was injected i.c.v. 5 min before each daily session consisting of 4 trials. On day 5 the platform was removed and the animals were tested for memory retention. The MCPG group had only eight animals, because two rats in this group became ill during the course of the experiment and were excluded. Morris water maze/cued taskk [2] Three weeks after the end of the spatial task experiment, some of the rats were re-tested in a cued version of the water maze. A 30 cm ×5 cm black tape was placed along the wall of the tank 15 cm above water level and centered around the submerged platform (see inset of Fig. 4). The tape represented the visual cue directing the animals to locate the platform. The tape and platform were left in the same location during each session, but they were moved to a new position every day. Their spatial relationship, however, was always maintained. The animals received 4 trials daily for 4 consecutive days. On the fifth day a probe trial was run as in the spatial task experiment. MCPG (20.8 μg, n=7) or vehicle (n=6) rats were injected i.c.v. every day 5 min before the session. The animals tested in this experiment had been used previously in the spatial version of the water maze. However, most of the animals that we employed had been treated with vehicle in the previous experiment. Contextual fear conditioningk [2] Groups of rats were placed individually in a rodent conditioning chamber (25×20×17 cm, San Diego Instr.) with a ventilation fan providing background noise. Inside the chamber eight infrared beams, 3 cm apart and 0.5 cm above the grid floor, monitored the animal activity. Shock delivery was controlled by a computer. A video-camera placed in front of the chamber provided recordings of every session for off-line behavioral analyses. The shock was a brief (1 sec, 0.5 mA) delivery of direct current produced by a grid floor shocker. On days 1 and 2, conditioning sessions consisted of three presentations of the shock during a 6-min session. On the third day, animals were placed again in the chamber but no shock was delivered. Motor activity was monitored by the computer system, which measured the number of beams interrupted by the animals in each of 12 30 sec intervals. Freezing, used as an index of conditioned fear, was assessed by an experimenter analyzing the videotapes after the experiment. Freezing was defined as the absence of all movement except respiratory-related movements (Phillips and LeDoux, 1992). The per cent of time spent freezing was calculated for each 1-min interval. Two different experiments were conducted. In the first experiment, rats received either vehicle (n=7) or MCPG (20.8 μg, n=7) i.c.v. 5 min before the start of the session for the 3-day experiment. In the second experiment, different groups of rats were injected s.c. with MK801 (n=8) or vehicle (n=8) 30 min before testing. Drugsk [2] (+)-α-Methyl-4-carboxyphenylglycine (MCPG) was employed in all experiments. MCPG (2.08 mg) was dissolved in equimolar NaOH (1 M), diluted to final volume with saline (0.9% NaCl) and the pH was then adjusted to 7.6±0.2. MCPG or vehicle was injected i.c.v. in 5 μl volume to each implanted animal. |
References |
|
Additional Infomation |
Metabotropic glutamate receptors (mGluRs) are critically involved in the maintenance of long-term potentiation (LTP) (Reymann and Matthies, 1989; Behnisch et al., 1991; Izumi et al., 1991; Bashir et al., 1993). In order to assess further the physiological role of MGluRs in LTP, we injected freely moving rats with the recently available, competitive mGluR antagonist (R,S)-alpha-methyl-4-carboxyphenylglycine (MCPG) intraventricularly and recorded extracellularly the population spike (PS) as well as the field excitatory postsynaptic potential (fEPSP) of the granule cells of the dentate gyrus in response to stimulation of fibers of the perforant path. MCPG was administered in two concentrations (A = 20 mM/5 microliters; B = 200 mM/5 microliters) either 30 min prior to or 5 min after LTP induction. Sodium chloride infusion served as a control. Normal synaptic transmission was not altered by MCPG. However, the mGluR antagonist inhibited LTP in a concentration-dependent manner. Concentration A did not influence the potentiation shortly after the tetanus. In the PS, short-term potentiation (STP), which is decremental in its time course, occurred normally, but in contrast to controls the potentiation declined back to baseline values after 2-3 hr. This dose also reduced the posttetanic increase in the slope function of the fEPSP, and led to a time course of potentiation similar to that for the PS. Concentration B completely abolished the tetanus-induced potentiation. This block was similar to that obtained for the NMDA antagonist 2-amino-5-phosphonopentanoate (AP5). Both MCPG concentrations had no influence on the time course of preestablished LTP. These effects seem to be due to the action of the (+)-isomer of MCPG, since intracerebroventricular application of the (-)-isomer was without effect on the duration and magnitude of LTP. In addition, we were interested in the mGluR subtypes involved in the blocking mechanism of MCPG. 1S,3R-aminocyclopentane-1,3-dicarboxic acid (ACPD)-activated PPI hydrolysis in hippocampal slices was competitively inhibited by MCPG at a concentration of 1 mM or higher. In contrast, this concentration of MCPG did not affect the reduction of forskolin-stimulated cAMP formation by ACPD. These results corroborate recent findings that mGluRs are required for the induction of LTP in CA1 and CA3 in vitro (Bashir et al., 1993; Sergueeva et al., 1993) and in vivo (Riedel and Reymann, 1993). The process of STP is found to be independent of mGluR activation.[3]
(S)-alpha-methyl-4-carboxyphenylglycine is a non-proteinogenic alpha-amino acid that is alanine in which the alpha-hydrogen is replaced by a 4-carboxyphenyl group (the S-enantiomer). It is a non-selective group I/group II metabotropic glutamate receptor (mGluR) antagonist. It has a role as a metabotropic glutamate receptor antagonist. Fragile X syndrome (FXS) is characterized by intellectual disability and autistic traits, and results from the silencing of the FMR1 gene coding for a protein implicated in the regulation of protein synthesis at synapses. The lack of functional Fragile X mental retardation protein has been proposed to result in an excessive signaling of synaptic metabotropic glutamate receptors, leading to alterations of synapse maturation and plasticity. It remains, however, unclear how mechanisms of activity-dependent spine dynamics are affected in Fmr knockout (Fmr1-KO) mice and whether they can be reversed. Here we used a repetitive imaging approach in hippocampal slice cultures to investigate properties of structural plasticity and their modulation by signaling pathways. We found that basal spine turnover was significantly reduced in Fmr1-KO mice, but markedly enhanced by activity. Additionally, activity-mediated spine stabilization was lost in Fmr1-KO mice. Application of the metabotropic glutamate receptor antagonist α-Methyl-4-carboxyphenylglycine (MCPG) enhanced basal turnover, improved spine stability, but failed to reinstate activity-mediated spine stabilization. In contrast, enhancing phosphoinositide-3 kinase (PI3K) signaling, a pathway implicated in various aspects of synaptic plasticity, reversed both basal turnover and activity-mediated spine stabilization. It also restored defective long-term potentiation mechanisms in slices and improved reversal learning in Fmr1-KO mice. These results suggest that modulation of PI3K signaling could contribute to improve the cognitive deficits associated with FXS.[1] In addition to MCPG, our study suggests that another interesting molecule to reverse phenotypes in Fmr1-KO mice is BpV, a PTEN inhibitor. Application of BpV enhances PI3K activity, a signaling pathway activated by many surface receptors including BDNF that also inhibits LTD (Jurado et al., 2010) and contributes to LTP signaling (Tang et al., 2002). Consistent with this, our experiments show that BpV could restore activity-dependent spine stabilization. These results thus suggest that in addition to an exaggerated LTD type of signaling, another defect present in Fmr1-KO mice could involve defective LTP mechanisms. Our LTP experiments support this interpretation and are in line with those of several other studies (Lauterborn et al., 2007; Meredith et al., 2007; Hu et al., 2008; but see also Krueger & Bear, 2011). A question, however, remains regarding the specific role of PI3K signaling in FXS. Two recent studies showed that PI3K activity and AKT phosphorylation are already upregulated in Fmr1-KO mice (Gross et al., 2010; Sharma et al., 2010), a result at variance with another study (Hu et al., 2008). It should be noted, however, that the PI3K-AKT signaling pathway is downstream of many cell surface receptors and implicated in many interactions with other systems, possibly through differential regulations of AKT phosphorylation sites (Hemmings & Restuccia, 2012). Although a precise understanding of the complex signaling mechanisms implicated in PI3K signaling is beyond the scope of this study, our data clearly show that BpV treatment enhanced AKT phosphorylation on the S473 site both under in vitro and in vivo conditions, and was able not only to reverse the deficits in spine dynamics observed in Fmr1-KO mice, but also to increase LTP and improve Fmr1-KO mice behavior in a Morris water maze learning task. Consistent with these results, PI3K signaling has been shown to contribute to LTP mechanisms (Tang et al., 2002), to be involved in BDNF signaling, which also rescued LTP in Fmr1-KO mice (Lauterborn et al., 2007), to regulate synaptogenesis and spinogenesis in hippocampal neurons (Jaworski et al., 2005; Cuesto et al., 2011), and more importantly to be also deficient in a mouse model of Angelman syndrome, another neurodevelopment disorder with severe cognitive deficits and autistic traits (Cao et al., 2013). It might therefore represent an interesting target for reversing cognitive deficits.[1] NMDA receptors play a key role in spatial and contextual learning and memory (see Squire, 1992). Our results suggest that mGlu receptors may have only a modulatory or secondary role. A recent study found that intra-hippocampal injections of MCPG did not affect working memory, but co-application of MCPG and a NMDA antagonist did (Ohno and Watanabe, 1996). A modulatory rather than a central role for mGlu receptors is also suggested by studies using LTP as a model for learning and memory. While NMDA receptor antagonists clearly block induction of LTP both in vitro (Collingridge et al., 1983) and in vivo (Morris et al., 1986; Abraham and Mason, 1988), the mGlu receptor antagonist MCPG has been reported to have mixed effects, sometimes depending on the technique used (see BenAri and Aniksztejn, 1995). Bashir et al. (1993)reported that MCPG blocked induction of LTP in hippocampal slices, but this result has not been confirmed by other investigators (Chinestra et al., 1993; Manzoni et al., 1994; Selig et al., 1995). Similarly, Riedel and Reymann (1993)found that MCPG blocked induction of LTP in vivo, but others (Bordi and Ugolini, 1995; BenAri and Aniksztejn, 1995) found no effect. In general, there is a good correlation between the effects of an antagonist compound on LTP and its effects on spatial memory tests (but see Saucier and Cain, 1995and Bannerman et al., 1995for further discussion). Because the present data show that MCPG causes some impairment on a spatial learning test but not in another, LTP might be expected to be only partially (Richter-Levin et al., 1994) or minimally affected by MCPG. Future work is needed with more potent and selective mGlu receptor antagonists to shed light on the relationship between different types of learning and the mechanism of LTP. In conclusion, our results show that the mGlu receptor antagonist MCPG disrupts the performance of rats in the spatial version of the water maze, but only using a high concentration of the drug and not in a cued version of the water maze, excluding an effect of the drug on sensory/perceptual faculties. Performance in a context-specific associative learning task was not affected by MCPG, but the NMDA blocker MK801 severely disrupted this performance as it did in the spatial version of the water maze. Future work might utilize these two behavioral paradigms to discriminate between the effects of ionotropic and metabotropic glutamate receptors in learning and memory.[2] |
Molecular Formula |
C10H10NNAO4
|
---|---|
Molecular Weight |
231.18
|
Exact Mass |
253.032
|
CAS # |
1303994-09-3
|
Related CAS # |
150145-89-4; 146669-29-6
|
PubChem CID |
90488871
|
Appearance |
Typically exists as solid at room temperature
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
5
|
Rotatable Bond Count |
1
|
Heavy Atom Count |
17
|
Complexity |
260
|
Defined Atom Stereocenter Count |
0
|
SMILES |
[Na+].[O-]C(C(C)(C1C=CC(C(=O)O)=CC=1)N)=O
|
InChi Key |
YGOTXTUQJLFNHB-UHFFFAOYSA-L
|
InChi Code |
InChI=1S/C10H11NO4.2Na/c1-10(11,9(14)15)7-4-2-6(3-5-7)8(12)13;;/h2-5H,11H2,1H3,(H,12,13)(H,14,15);;/q;2*+1/p-2
|
Chemical Name |
disodium;4-(1-amino-1-carboxylatoethyl)benzoate
|
Synonyms |
(RS)-MCPG disodium salt; 1303994-09-3; Benzeneacetic acid, alpha-amino-4-carboxy-alpha-methyl-, sodium salt (1:1); disodium;4-(1-amino-1-carboxylatoethyl)benzoate; (R,S)-MCPG sodium salt; (RS)-alpha-Methyl-4-carboxyphenylglycine disodium salt;
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.3256 mL | 21.6282 mL | 43.2563 mL | |
5 mM | 0.8651 mL | 4.3256 mL | 8.6513 mL | |
10 mM | 0.4326 mL | 2.1628 mL | 4.3256 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.